These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38112434)

  • 21. Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.
    Eslam M; George J
    J Hepatol; 2020 Dec; 73(6):1575. PubMed ID: 32933781
    [No Abstract]   [Full Text] [Related]  

  • 22. Time to revise the definition of NAFLD: A purist vision.
    Mantovani A
    Dig Liver Dis; 2019 Mar; 51(3):457-458. PubMed ID: 30683616
    [No Abstract]   [Full Text] [Related]  

  • 23. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.
    Ilagan-Ying YC; Banini BA; Do A; Lam R; Lim JK
    Curr Gastroenterol Rep; 2023 Oct; 25(10):213-224. PubMed ID: 37768417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging.
    Koch LK; Yeh MM
    Ann Diagn Pathol; 2018 Dec; 37():83-90. PubMed ID: 30312882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease.
    Xie C; Liu K; Xie Y; Liu S; Ji B
    Clin Res Hepatol Gastroenterol; 2024 Feb; 48(2):102264. PubMed ID: 38142587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
    Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
    Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases].
    Chen L; Jiang LN; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):805-809. PubMed ID: 37723061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
    Suzuki K; Tamaki N; Kurosaki M; Takahashi Y; Yamazaki Y; Uchihara N; Tanaka Y; Miyamoto H; Yamada M; Keitoku T; Okada R; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Izumi N
    Hepatol Res; 2024 Jun; 54(6):600-605. PubMed ID: 38234088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.
    Kim GA; Moon JH; Kim W
    Clin Mol Hepatol; 2023 Oct; 29(4):831-843. PubMed ID: 37634892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leukocyte cell-derived chemotaxin 2 correlates with pediatric non-alcoholic fatty liver disease.
    Paine-Cabrera D; Harvey LK; Robarts DR; Pritchard MT; Thyfault J; Weinman SA; Apte U; Slowik V
    Clin Transl Sci; 2023 Dec; 16(12):2719-2728. PubMed ID: 37877453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-alcoholic fatty liver disease: Definition and subtypes.
    Han SK; Baik SK; Kim MY
    Clin Mol Hepatol; 2023 Feb; 29(suppl):S5-S16. PubMed ID: 36577427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
    Targher G; Byrne CD; Tilg H
    Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From NAFLD to MASLD: When metabolic comorbidity matters.
    Hong S; Sun L; Hao Y; Li P; Zhou Y; Liang X; Hu J; Wei H
    Ann Hepatol; 2024; 29(2):101281. PubMed ID: 38135250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.
    Song R; Li Z; Zhang Y; Tan J; Chen Z
    Liver Int; 2024 Apr; 44(4):1051-1060. PubMed ID: 38293788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018.
    Wang T; Xi Y; Raji A; Crutchlow M; Fernandes G; Engel SS; Zhang X
    Ann Hepatol; 2024; 29(1):101154. PubMed ID: 37742743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fatty liver index (FLI) and prediction of new cases of non-alcoholic fatty liver disease: A population-based study of northern Iran.
    Motamed N; Faraji AH; Khonsari MR; Maadi M; Tameshkel FS; Keyvani H; Ajdarkosh H; Karbalaie Niya MH; Rezaie N; Zamani F
    Clin Nutr; 2020 Feb; 39(2):468-474. PubMed ID: 30922791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fatty Liver Disease: Enter the Metabolic Era.
    Wegermann K; Moylan C; Naggie S
    Curr HIV/AIDS Rep; 2023 Dec; 20(6):405-418. PubMed ID: 37882965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.